Key Highlights

● Quarterly net revenue was about 81 million Canadian dollars, up about 13%.

● The net loss narrowed by about two-thirds to roughly 15 million Canadian dollars.

● Reported gross margin rose to about 27%, or about 31% excluding an inventory step-up charge.

● Cash fell to roughly 337 million Canadian dollars from about 365 million at fiscal year-end.

Canopy Growth (NASDAQ:CGC), the Canadian cannabis producer listed on the Nasdaq under the ticker CGC, remains one of the sector's most closely watched turnaround stories. Its most recent earnings report covered the first quarter of fiscal 2027 and was released on Friday, August 7.

The quarter, which ended June 30, was the first full period to include the contribution of MTL Cannabis, a Canadian medical cannabis producer that Canopy acquired during its last fiscal year. Revenue grew in every business line, the net loss shrank sharply, and gross margins improved. At the same time, cash declined, debt edged higher and the company still reports an adjusted EBITDA loss.

All figures are in Canadian dollars.

What did Canopy Growth report for its first quarter of fiscal 2027?

According to the company's release, consolidated net revenue was about $81 million, up about 13% from roughly $72 million in the same quarter a year earlier. The company emphasized that every business contributed to the increase: cannabis revenue rose about 14% to roughly $65 million, and the Storz and Bickel vaporizer business grew about 6% to roughly $16 million.

The bottom line improved by a wide margin. Canopy reported a net loss of about $15 million, or 3 cents per share, compared with a loss of about $45 million, or 24 cents per share, in the prior-year quarter. Part of the per-share improvement reflects a larger share count after the company raised equity during the previous fiscal year, so the per-share comparison is less dramatic than it appears, but the total loss fell by roughly two-thirds on its own.

Adjusted EBITDA, a non-GAAP measure that excludes items such as depreciation, interest and certain one-time charges, was a loss of about $3 million. That is an improvement of about $5 million, or 59%, from a loss of roughly $8 million a year earlier. Canopy has not yet reached positive adjusted EBITDA, though management has said it expects to do so during the current fiscal year.

How did Canopy Growth's Canadian medical business perform?

Canadian medical cannabis revenue rose about 22% to roughly $26 million. The company credited a higher number of insured customers and the contribution from MTL Cannabis, partly offset by a lower reimbursement rate from Veterans Affairs Canada. That agency reimburses eligible veterans for medical cannabis, and a reduction in the rate paid affects the revenue Canopy collects per patient.

The result is notable because the prior fiscal year had already included a response to that reimbursement change. In its June annual release, Canopy said it addressed the lower reimbursement through pricing, product mix and patient retention efforts, and it described itself as Canada's leading medical cannabis provider by revenue following the MTL deal.

Medical cannabis in Canada is a different business from adult-use. Patients are often covered by private insurers or government programs, and loyalty tends to be higher, which supports steadier revenue. The trade-off is that payers have pushed back on price in some cases, as the veterans rate shows. For Canopy, the segment's growth is a main reason the consolidated revenue line improved even with softer demand in other areas, and it will be watched for signs that price pressure is moderating.

What is happening with Canopy Growth's adult-use sales and ranking?

Canadian adult-use net revenue was about $30 million, up about 10%. The company said the gain was mainly driven by flower sales tied to MTL, partly offset by lower opportunistic bulk sales, which are one-off wholesale transactions with other licensed producers that tend to be uneven from quarter to quarter.

The release stated that Canopy ranks sixth overall in Canada's adult-use market and ranks in the top two positions in premium flower, infused pre-rolls, and oils and softgels. It also referred to product launches, including an expansion of the Claybourne Frosted Flyers pre-roll line and new softgel pack sizes under the Spectrum brand.

A sixth-place overall rank signals that the Canadian recreational market remains fragmented and competitive. Retail price points have fallen across the industry in recent years, and shelf space is contested by dozens of licensed producers as well as the illicit market. Canopy's strategy of concentrating on premium and specialty formats is aimed at limiting exposure to the lowest-priced segments, but the company still has to prove that those categories can deliver consistently higher margins at scale.

How did international cannabis and Storz and Bickel contribute to Canopy Growth's quarter?

International cannabis revenue grew about 10% to roughly $10 million, led by Poland, according to the release. Canopy has also relaunched its Tweed brand in the German medical market. Europe has been a focus because medical cannabis demand there is expanding, although the prior fiscal year release noted European supply constraints that held back some sales.

Storz and Bickel, the vaporizer maker, reported net revenue of about $16 million, up about 6%. Its gross margin jumped to about 48% from about 29% a year earlier, helped, according to the company, by cost reductions and a recovery of U.S. tariff costs.

The segment had a difficult fiscal year before this. Full-year revenue fell about 14%, and Canopy recorded goodwill and brand impairments tied to Storz and Bickel in its fourth quarter. The latest quarter therefore shows stabilization, not a full recovery, and the margin improvement may partly reflect the timing of tariff recoveries, which could prove temporary. The company noted a launch of the VEAZY portable vaporizer last September as one of the drivers of recent product activity.

Why did Canopy Growth's gross margin improve?

Reported consolidated gross margin was about 27%, up from about 25% a year earlier. Adjusted for a charge of about $2.5 million related to stepping up the value of MTL Cannabis inventory in acquisition accounting, the margin was about 31%. The step-up is an accounting effect: inventory acquired in a deal is recorded at fair value, which raises its cost when it moves through and temporarily lowers the margin.

Within cannabis, gross margin was about 22% as reported and about 26% adjusted, compared with an adjusted figure of about 24% in the prior-year quarter. That is an improvement, but the level is still low by the standards of medical-focused peers, which typically report higher adjusted margins.

The company has said that stronger cultivation practices should lift cannabis margins over the course of the fiscal year, and it flagged lower operating expenses from cost discipline. The fourth quarter of the prior year included inventory charges of about $10.5 million, which dragged the reported margin to about 12%, so the swing since then is large. The sustainability of the improvement depends on yields, mix and whether the MTL integration delivers the supply benefits that management has described.

What does Canopy Growth's cash and debt position look like?

Cash and equivalents ended June at about $337 million, down from about $365 million at the end of March. Total debt was about $240 million, consisting of roughly $29 million current and about $211 million long-term, compared with about $233 million at fiscal year-end.

Free cash flow was an outflow of about $26 million, compared with an outflow of about $12 million a year earlier. The company attributed the larger outflow mainly to working capital timing, which is a normal swing factor but one that reverses only if receivables are collected and inventory is converted into sales as expected.

On a net basis the company retained a net cash position at fiscal year-end of about $131 million, compared with net debt of about $173 million a year earlier. That improvement followed a recapitalization completed in January, and proceeds from share and warrant issuances of roughly $374 million in the last fiscal year. The balance sheet is therefore stronger than it was, but the quarter showed that cash is still being consumed rather than generated.

What did the prior Canopy Growth fiscal year show?

For the fiscal year ended March 31, Canopy reported net revenue of about $285 million, up about 6%, and a net loss from continuing operations of about $263 million, which was about half the loss of the year before. The loss included asset impairment and restructuring charges of about $67 million, mainly tied to Storz and Bickel.

Adjusted EBITDA for that year was a loss of about $20 million. General and administrative expenses fell about 6% to roughly $160 million. Management said it expects positive adjusted EBITDA during the current fiscal year, net revenue growth across the business, and a stronger improvement in the second half.

The June release also disclosed a material weakness in internal control over financial reporting and referenced restatement of prior financial statements. A material weakness means there is a reasonable possibility that a material misstatement might not be prevented or detected in a timely way. It does not by itself mean that reported figures are wrong, and whether it has since been remediated is not described.

How is Canopy Growth integrating MTL Cannabis?

The MTL Cannabis acquisition closed during the last fiscal year, with a net cash outflow of about $41.5 million for the acquisition of subsidiaries. The business supplies flower for both the medical and adult-use channels, and management has said it expects supply and synergy benefits as integration proceeds.

The company said that integration will continue into the first half of calendar 2027, and it is the main reason management expects the second half of the fiscal year to show a larger year-over-year improvement. In practice, integration involves consolidating cultivation and processing, aligning product lines and removing duplicate overhead. Those steps typically cost money before they save it, which can explain why free cash flow worsened in the quarter.

There is also a revenue effect to separate out. Because MTL was not part of the business for the whole of the prior-year comparison period, part of the 13% growth is inorganic. The release did not provide an organic growth figure, so the underlying pace of growth at the legacy business cannot be stated precisely.

How does Canopy Growth compare with other Canadian cannabis producers?

Canopy sits between two models in the Canadian group. Aurora Cannabis (NASDAQ:ACB) has focused almost entirely on global medical cannabis and has a debt-free balance sheet, and SNDL (NASDAQ:SNDL) relies on retail with a large book of stakes in other firms. Tilray Brands (NASDAQ:TLRY) has diversified into beverages and distribution. Canopy combines a Canadian medical lead, a premium adult-use business and a hardware unit.

That breadth is both a strength and a challenge. It diversifies revenue, as the first quarter showed, but it also means management must address several different market dynamics at once, from veterans reimbursement to German import licensing to U.S. tariff rules affecting vaporizers. It also carries more debt than some peers, with total borrowings of about $240 million set against its cash.

Canopy remains the only one of the four with a reported adjusted EBITDA loss in its most recent quarter, which frames its progress: the trend is positive, but the destination has not been reached. The company's own wording stresses momentum, and the data support improvement while leaving the earnings milestone for later quarters.

What should market participants watch next at Canopy Growth?

The next scheduled event is the second quarter fiscal 2027 report, which would normally be issued in early November, though a date has not been confirmed. The key figures will be adjusted EBITDA, which management has said should turn positive during the year, and free cash flow, which swung the wrong way in the first quarter.

Other items include progress on the MTL integration, any further impairments, the effect of the veterans reimbursement rate on Canadian medical revenue, and whether Storz and Bickel can maintain its improved margin once the tariff recovery fades. The status of the material weakness in internal controls is another open question.

The company's stated expectation is that results should improve further in the second half, and the available evidence shows movement in that direction. Still, the same release contained a cash decline and a larger debt balance, which is why the quarter reads as progress with unfinished business.